MoleSense Raises €156K To Develop Smart Wearables For Maternity Care

The devices will non-invasively track biochemical markers in high-risk pregnancies, supporting data-driven decisions and proactive maternal care.

Preterm birth and pregnancy complications remain major challenges in maternal healthcare. When a mother’s water breaks prematurely, doctors must choose between delaying delivery and risking infection or inducing birth and risking complications often without reliable data, leading to invasive tests and difficult, high-stakes decisions.

Read Also - Vista Equity Partners Takes Majority Stake In Nexthink To Drive Next Phase Of Growth

MoleSense has developed a new generation of molecular wearables that track inflammatory proteins and steroid hormones in real time through non-invasive sweat monitoring using a “wear and forget” device.

By combining personalized molecular data with biology-aware machine intelligence, the technology delivers real-time insights for early diagnosis and targeted care.

Founded by EPFL PhDs Gian Luca Barbruni and Ata Golparvar, MoleSense leverages deep expertise in nano-engineering and wearables to revolutionize pregnancy management a market impacting over eight million pregnancies annually across Switzerland, Europe, and the U.S.

Targeting the USD 110 billion women’s healthcare device sector, the startup will use the CHF 150,000 Venture Kick grant to validate its technology and advance toward regulatory approval and early market entry.

“Venture Kick challenged us to think bigger, move faster, and sharpen our vision,” commented CEO Gian Luca Barbruni.

About MoleSense

MoleSense is revolutionizing women’s health with molecular wearables advanced medical devices that continuously and non-invasively track biochemical markers like proteins and hormones. By combining personalized molecular data with biology-aware AI, MoleSense enables proactive, data-driven care for high-risk pregnancies and sets a new standard in maternal healthcare innovation.